![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Thorough QT/QTc Trial to Evaluate the Effect of the HIV-1 Attachment Inhibitor BMS-626529, Administered as its Prodrug, BMS-663068, on QTc Intervals
|
|
|
Reported by Jules Levin
15th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy
19-21 May 2014, Washington DC, USA
Hruska MW, Savant IA, Anderson JA, Shah V, Chang I, Adamczyk R, Furlong M, Hanna GJ, Bertz R, Zhu L
Bristol-Myers Squibb, Princeton, NJ, USA
![Pharm1.gif](../images/052314/052314-1/Pharm1.gif)
![Pharm2.gif](../images/052314/052314-1/Pharm2.gif)
![Pharm3.gif](../images/052314/052314-1/Pharm3.gif)
![Pharm4.gif](../images/052314/052314-1/Pharm4.gif)
![Pharm5.gif](../images/052314/052314-1/Pharm5.gif)
![Pharm6.gif](../images/052314/052314-1/Pharm6.gif)
![Pharm7.gif](../images/052314/052314-1/Pharm7.gif)
![Pharm8.gif](../images/052314/052314-1/Pharm8.gif)
![Pharm9.gif](../images/052314/052314-1/Pharm9.gif)
![Pharm10.gif](../images/052314/052314-1/Pharm10.gif)
![Pharm11.gif](../images/052314/052314-1/Pharm11.gif)
![Pharm12.gif](../images/052314/052314-1/Pharm12.gif)
![Pharm13.gif](../images/052314/052314-1/Pharm13.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|